Nick Barkham

855 total citations
25 papers, 563 citations indexed

About

Nick Barkham is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Nick Barkham has authored 25 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 13 papers in Immunology and 8 papers in Hematology. Recurrent topics in Nick Barkham's work include Spondyloarthritis Studies and Treatments (14 papers), Psoriasis: Treatment and Pathogenesis (11 papers) and Rheumatoid Arthritis Research and Therapies (9 papers). Nick Barkham is often cited by papers focused on Spondyloarthritis Studies and Treatments (14 papers), Psoriasis: Treatment and Pathogenesis (11 papers) and Rheumatoid Arthritis Research and Therapies (9 papers). Nick Barkham collaborates with scholars based in United Kingdom, South Korea and Australia. Nick Barkham's co-authors include Paul Emery, E. Hensor, Helen Keen, Lorna Cawkwell, Alexander Fraser, Laura C. Coates, Dennis McGonagle, Alexander N. Bennett, Philip O’Connor and Alan Tennant and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

Nick Barkham

21 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nick Barkham United Kingdom 10 512 315 171 49 27 25 563
Ivette Essers Netherlands 10 466 0.9× 284 0.9× 127 0.7× 45 0.9× 16 0.6× 19 533
Silvia Scriffignano Italy 13 368 0.7× 290 0.9× 161 0.9× 9 0.2× 13 0.5× 49 430
Kirsten Karberg Germany 9 349 0.7× 95 0.3× 91 0.5× 90 1.8× 6 0.2× 40 428
Elisa Muñoz-Gomáriz Spain 10 351 0.7× 212 0.7× 93 0.5× 93 1.9× 9 0.3× 14 480
Kurt De Vlam Belgium 11 651 1.3× 267 0.8× 169 1.0× 134 2.7× 21 0.8× 14 739
Rafael Ariza Ariza Spain 10 218 0.4× 112 0.4× 70 0.4× 15 0.3× 26 1.0× 26 288
Dinny Wallis United Kingdom 8 273 0.5× 179 0.6× 86 0.5× 25 0.5× 31 1.1× 15 357
Cristina Fernández‐Carballido Spain 12 311 0.6× 210 0.7× 108 0.6× 16 0.3× 8 0.3× 50 384
Mohamed Bedaiwi Saudi Arabia 11 188 0.4× 97 0.3× 74 0.4× 13 0.3× 31 1.1× 36 295
Anna Deminger Sweden 8 297 0.6× 132 0.4× 54 0.3× 55 1.1× 6 0.2× 16 356

Countries citing papers authored by Nick Barkham

Since Specialization
Citations

This map shows the geographic impact of Nick Barkham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick Barkham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick Barkham more than expected).

Fields of papers citing papers by Nick Barkham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nick Barkham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick Barkham. The network helps show where Nick Barkham may publish in the future.

Co-authorship network of co-authors of Nick Barkham

This figure shows the co-authorship network connecting the top 25 collaborators of Nick Barkham. A scholar is included among the top collaborators of Nick Barkham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nick Barkham. Nick Barkham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gupta, Latika, et al.. (2022). Effectiveness and safety of secukinumab in ankylosing spondylitis: real-life data from Midlands Ankylosing Spondylitis Collaboration (MASC). Rheumatology Advances in Practice. 7(1). rkad029–rkad029. 1 indexed citations
3.
4.
Baraliakos, Xenofon, et al.. (2022). Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series. SHILAP Revista de lepidopterología. 10(1). e05205–e05205. 3 indexed citations
5.
6.
7.
Scotton, William J., et al.. (2019). 10. Warning: statin-induced autoimmune necrotising myositis. Rheumatology Advances in Practice. 3(Supplement_1).
8.
9.
10.
Prabu, A., et al.. (2018). Knowledge of features of inflammatory back pain in primary care in the West Midlands: a cross-sectional survey in the United Kingdom. Rheumatology International. 38(10). 1859–1863. 5 indexed citations
11.
Barkham, Nick, et al.. (2018). The current standard of care and the unmet needs for axial spondyloarthritis. Lara D. Veeken. 57(suppl_6). vi10–vi17. 20 indexed citations
12.
Hamilton, Louise, Nick Barkham, Ashok K. Bhalla, et al.. (2016). BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Lara D. Veeken. 56(2). 313–316. 36 indexed citations
13.
Barkham, Nick, Laura C. Coates, Helen Keen, et al.. (2010). Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Annals of the Rheumatic Diseases. 69(11). 1926–1928. 56 indexed citations
14.
Gilworth, Gill, Paul Emery, Nick Barkham, et al.. (2009). Reducing work disability in Ankylosing Spondylitis – development of a work instability scale for AS. BMC Musculoskeletal Disorders. 10(1). 68–68. 33 indexed citations
15.
Barkham, Nick, Helen Keen, Laura C. Coates, et al.. (2009). Clinical and imaging efficacy of infliximab in HLA–B27–Positive patients with magnetic resonance imaging–determined early sacroiliitis. Arthritis & Rheumatism. 60(4). 946–954. 216 indexed citations
16.
Freeston, Jane, Nick Barkham, E. Hensor, Paul Emery, & Alexander Fraser. (2007). Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies. Joint Bone Spine. 74(2). 140–143. 38 indexed citations
17.
Freeston, Jane, Nick Barkham, E. Hensor, Paul Emery, & Alexander Fraser. (2007). Spondylarthrite ankylosante, positivité de HLA-B27 et utilisation des biothérapies. Revue du Rhumatisme. 74(3). 232–236. 1 indexed citations
18.
Keat, Andrew, Nick Barkham, A K Bhalla, et al.. (2005). BSR guidelines for prescribing TNF-α blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Lara D. Veeken. 44(7). 939–947. 71 indexed citations
19.
Barkham, Nick, Kok Ooi Kong, Alan Tennant, et al.. (2005). The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Lara D. Veeken. 44(10). 1277–1281. 39 indexed citations
20.
Barkham, Nick, et al.. (2004). How to diagnose axial spondyloarthropathy early. Annals of the Rheumatic Diseases. 63(5). 471–472. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ivette Essers Breakdown of academic impact, for papers by Silvia Scriffignano Breakdown of academic impact, for papers by Kirsten Karberg Breakdown of academic impact, for papers by Elisa Muñoz-Gomáriz Breakdown of academic impact, for papers by Kurt De Vlam Breakdown of academic impact, for papers by Rafael Ariza Ariza Breakdown of academic impact, for papers by Dinny Wallis Breakdown of academic impact, for papers by Cristina Fernández‐Carballido Breakdown of academic impact, for papers by Mohamed Bedaiwi Breakdown of academic impact, for papers by Anna Deminger
Rankless by CCL
2026